Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - GenVec, Inc. (NasdaqNM:GNVC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
65 West Watkins Mill Road
Gaithersburg, MD 20878
Phone: (240) 632-0740
Fax: (240) 632-0735
Employees (last reported count): 84
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 39%
·Over the last 6 months:
 · 8 insider buys; 69.0K shares (0.9% of insider shares)
 · 2 insider sells; 458.0K shares
  (6.1% of insider shares)
·Institutional: 31% (51% of float)
(27 institutions)
·Net Inst. Buying: 605.0K shares (+9.72%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
GenVec, Inc. develops gene-based products that cause medically beneficial proteins to be produced at the site of disease. Local production of proteins over a sustained period may allow the proteins to have a potential benefit, while minimizing the overall toxicity that can occur when large doses of a protein are introduced directly into the body. The Company's areas of focus are diseases of the heart and blood vessels, cancer and diseases of the eye. The Company is developing products consisting of genes and vehicles, called vectors, which deliver those genes into cells at the site of the disease. The Company has specialized in the use and improvement of particular types of vectors called adenovectors. These vectors are derived from adenoviruses, which are viruses that cause ailments such as the common cold. The Company's adenovector technology allows it to test the therapeutic benefit of genes in a broad range of animal models of human disease.
More from Market Guide: Expanded Business Description

Financial Summary
GenVec, Inc. develops gene-based products that cause the production of therapeutic proteins at the site of disease, with a current focus on cardiovascular disease, oncology and ophthalmology. For the six months ended 6/30/01, total revenues fell 52% to $4.1 million. Net loss totaled $7 million, up from $2.1 million. Results reflect reduced amounts earned under the research support agreement with Pfizer and increased general and administrative expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Herbert Conrad, 68
Chairman
--  
Paul Fischer, Ph.D., 51
Pres, CEO, Director
$310K
Jeffrey Church, 44
CFO, Treasurer, Sec.
226K
Thomas Smart, 37
Sr. VP, Corp. Devel.
218K
C. Richter King, Ph.D, 46
VP, Research
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GNVCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 11-July-2001
$2.05 
Recent Price$3.00 
52-Week High
on 12-Dec-2000
$11.75 
Daily Volume (3-month avg)138.1K
Daily Volume (10-day avg)55.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change-50.0%
26-Week Change
relative to S&P500
-45.6%
Share-Related Items
Market Capitalization$54.2M
Shares Outstanding18.1M
Float11.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.12 
Earnings (ttm)-$2.23 
Earnings (mrq)-$0.21 
Sales (ttm)$0.86 
Cash (mrq)$0.96 
Valuation Ratios
Price/Book (mrq)1.41 
Price/EarningsN/A 
Price/Sales (ttm)3.47 
Income Statements
Sales (ttm)$9.42M
EBITDA (ttm)-$10.8M
Income available to common (ttm)-$12.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-31.18%
Return on Equity (ttm)-44.90%
Financial Strength
Current Ratio (mrq)6.18 
Debt/Equity (mrq)0.17 
Total Cash (mrq)$17.2M
Short Interest
As of 8-Aug-2001
Shares Short2,000 
Percent of Float0.0%
Shares Short
(Prior Month)
1,000 
Short Ratio0.03 
Daily Volume63.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.